Anil Singhal

Anil Singhal currently works at Trishula Therapeutics, Inc., as President, Chief Executive Officer & Director from 2021, TriSalus Operating Life Sciences, Inc., as Director from 2018, Werewolf Therapeutics, Inc., as Independent Director from 2025, Accelerator Services Corp, as Advisory Board, American Society of Clinical Oncology, Inc., as Member from 2007, and The American Association of Cancer Research, as Member from 2005.
Dr. Singhal also formerly worked at Adicet Therapeutics, Inc., as President, Chief Executive Officer & Director from 2019 to 2020, Nektar Therapeutics, as Director from 2005 to 2007, The Biomembrane Institute, as Director from 1986 to 1996, TriSalus Life Sciences, Inc., as Independent Director from 2023 to 2024, Light Sciences Oncology, Inc., as Vice President from 1999 to 2003, Pacific Pharmaceuticals, Inc., as Vice President from 1996 to 1999, Xerion Pharmaceuticals AG, as Vice President from 2003 to 2005, OncoResponse, Inc., as Chief Scientific Officer, AbbVie, Inc., as Vice President-Early Oncology Development from 2013 to 2018, and Abbott Laboratories, as Vice President from 2012 to 2013.
Dr. Singhal received his Masters Business Admin degree from the University of Washington, doctorate degree from Rutgers State University of New Jersey, and undergraduate degree from Panjab University Chandigarh.